NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,419.46 +212.33 (+1.17%) CRUDE OIL
79.08 +0.13 (+0.16%) GOLD FUTURES
2,309.30 -0.30 (-0.01%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,486.77 +1,881.68 (+4.13%)
ImmunityBio, Inc. (IBRX)
After hours:
| Previous close | 8.54 |
| Open | 8.72 |
| Bid | 8.88 x 100 |
| Ask | 10.62 x 200 |
| Day's range | 8.25 - 9.12 |
| 52-week range | 1.25 - 10.53 |
| Volume | |
| Avg. volume | 6,817,281 |
| Market cap | 6.073B |
| Beta (5Y monthly) | 0.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.15 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.50 |
Business WireImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
CULVER CITY, Calif., May 02, 2024--ImmunityBio, Inc. (NASDAQ: IBRX), has signed an exclusive global arrangement with the Serum Institute of India, the world’s largest manufacturer of vaccines by number of doses produced, to supply ImmunityBio with Bacillus Calmette-Guerin (BCG). The agreement covers the manufacturing of standard BCG (sBCG) that is currently approved for use outside the U.S., as well as a next-generation recombinant BCG (iBCG) undergoing testing, intended for use in combination w
Business WireImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
CULVER CITY, Calif., April 30, 2024--The Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio, Inc. (NASDAQ: IBRX), a next-generation immunotherapy company, will discuss the implications of the recent FDA approval of ANKTIVA® (nogapendekin alfa inbakicept-pmln) for use in combination with bacillus Calmette-Guerin (BCG) for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors at the American Urological Association An
Business WireImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
CULVER CITY, Calif., April 25, 2024--ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab) and standard-of-care chemotherapy to be discussed during the upcoming conference call. The results continue to reinforce ImmunityBio’s belief in the unique mechanism of action of ANKTIVA (N-803, or
